Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU
{ Posted on Mar 09 2010 by admin }
Millennium: The Takeda Oncology Company today announced the presentation of safety, pharmacokinetic and efficacy data from the Phase I portion of a Phase I/II clinical trial evaluating TAK-700 in patients with metastatic castration resistant prostate cancer (mCRPC). These data were ...Read More »

